Neurological diseases

Roche Pays $55M Upfront to Manifold Bio in $2B+ Deal for AI-Guided Next-Gen Brain Shuttles

1 month ago talkbio0Tagged AI drug discovery, BBB, Blood - brain barrier anatomy, Manifold Bio, milestones, Neurological diseases, research, Roche (company), shuttles, therapeutic payloads, upfront payment

Roche; Manifold Bio; blood-brain barrier; BBB shuttles; neurological diseases; AI drug discovery; research deal; upfront payment; milestones; therapeutic payloads

Aerska Launches with $21M to Use Brain ‘Shuttles’ for RNAi Delivery in Neurological Diseases

2 months ago talkbio0Tagged Aerska, Alzheimer 's, antibody-oligonucleotide, Blood - brain barrier anatomy, brain shuttles, Gene Silencing, Immunostimulating conjugate (antigen), Irish (ethnic group), Neurological diseases, Parkinson 's, Precision Medicine, RNA Interference

Aerska; Irish biotech; RNA interference (RNAi); brain shuttles; blood-brain barrier; neurological diseases; Alzheimer’s; Parkinson’s; gene silencing; precision medicine; antibody-oligonucleotide conjugates

Merck KGaA Forms $2 Billion Neurological Disease Pact with Skyhawk Therapeutics

4 months ago talkbio0Tagged Drug Discovery, Merck KGaA, milestone payments, Neurological diseases, RNA Splicing, Skyhawk, SkySTAR platform, strategic collaboration

Merck KGaA; Skyhawk Therapeutics; neurological diseases; RNA splicing; SkySTAR platform; drug discovery; strategic collaboration; milestone payments

Tenvie Therapeutics Launches with $200 Million to Revolutionize Neurological Disease Treatment

11 months ago talkbio0Tagged Arch of foot, Denali, F-Prime Capital, Mubadala, Neurological diseases, Partner in relationship, small molecule therapies, Tenvie, venture

Tenvie Therapeutics, neurological diseases, small molecule therapies, Denali Therapeutics, ARCH Venture Partners, F-Prime Capital, Mubadala Capital

Novartis and Monte Rosa Collaborate on $2.2B Molecular Glue Degrader Alliance

1 year ago talkbio0Tagged Biopharma, Collaboration, molecular glue, Monte Rosa, Neoplasms, Neurological diseases, Novartis, Protein Degradation, Metabolic

Novartis, Monte Rosa, molecular glue degraders, biopharma collaboration, protein degradation, oncology, neurological diseases

Roche and Dyno Therapeutics Launch $1B+ Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Neurological Diseases

1 year ago talkbio0Tagged AAVS1 gene, Cloning Vectors, Collaboration, Dyno, gene delivery process, gene therapy, LEAP, Neurological diseases, Roche (company), Technology

Roche, Dyno Therapeutics, AAV gene therapy vectors, Neurological diseases, AI-driven gene delivery, LEAP technology, Gene therapy collaboration

Roche Revisits Dyno for AAV Technology with $50M Upfront Payment

1 year ago talkbio0Tagged AAV, AAVS1 gene, Dyno, gene therapy, Neurological diseases, Roche (company), strategic partnership, Technology

Roche, Dyno Therapeutics, AAV technology, gene therapy, neurological diseases, strategic partnership

Roche Partners with Ascidian in $1.8 Billion RNA Exon Editing Deal for Neurological Diseases

1 year ago talkbio0Tagged Ascidiacea, Neurological diseases, Partnership, RNA exon editing, Roche (company)

Roche, Ascidian, RNA exon editing, neurological diseases, partnership, therapeutics

Acorda Therapeutics Concludes $185M Asset Sale with Merz amid Bankruptcy Filing Following Disappointing Sales

2 years ago talkbio0Tagged Acorda, asset, Bankruptcy filing, Biogen returns, Declining sales, ex-US, Fampyra, Generic competition, Merz, Multiple Sclerosis drug, Neurological diseases, year

Acorda Therapeutics, $185M asset sale, Merz, Bankruptcy filing, Years of disappointing sales, Multiple Sclerosis drug Fampyra, Biogen returns ex-US rights, Generic competition, Declining sales, Neurological diseases